NCT04945772View on ClinicalTrials.gov

Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 13, 2021

Primary Completion Date

February 27, 2023

Study Completion Date

January 18, 2024

Conditions
Retinitis PigmentosaRetinitisRetinal DiseasesEye DiseasesEye Diseases, HereditaryRetinal DystrophiesRetinal Degeneration
Interventions
BIOLOGICAL

Gene Therapy Product-MCO-010

The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette

PROCEDURE

Sham Injection

Sham Injection

Trial Locations (6)

32503

Nanoscope Clinical Site, Pensacola

58103

Nanoscope Clinical Site, Fargo

77030

Nanoscope Clinical Site, Houston

78503

Nanoscope Clinical Site, McAllen

90211

Nanoscope Clinical Site, Beverly Hills

00612

Nanoscope Clinical Site, Arecibo

Sponsors
All Listed Sponsors
lead

Nanoscope Therapeutics Inc.

INDUSTRY

NCT04945772 - Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] | Biotech Hunter | Biotech Hunter